Teva, Glaxo Settle Suit Over Generic Lamictal

Law360, New York (February 17, 2005, 12:00 AM EST) -- Teva Pharmaceutical and GlaxoSmithKline have settled their patent litigation over Glaxo’s Lamictal with a deal under which Teva will be allowed to launch an exclusive generic version later this year.

Teva, the world's largest generic drugmaker, said it will have the right to sell a generic version of Lamictal chewable tablets in the United States at doses of 5 milligrams and 25 milligrams no later than June 2005.

Teva said the exclusive license from Glaxo will require it to pay the drugmaker royalties on sales....
To view the full article, register now.